study_start,study_end,eligible_patients,treated_patients,treated_sotrovimab,treated_molnupiravir,treated_casirivimab,high_risk_cohort_2plus,high_risk_cohort_lower,high_risk_cohort_upper,non_eligible_patients,deregistered
2021-12-11,2022-02-05,67440,5370,2870,2450,50,1200,1,7,1050,650
